Shenzhen Breo Technology Valuation
Is 688793 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688793 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 688793 (CN¥30.35) is trading below our estimate of fair value (CN¥51.15)
Significantly Below Fair Value: 688793 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688793?
Key metric: As 688793 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 688793's PS Ratio? | |
|---|---|
| PS Ratio | 2.2x |
| Sales | CN¥1.17b |
| Market Cap | CN¥2.56b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | -181.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 688793's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.1x | ||
603059 Perfect Group | 1.9x | 26.3% | CN¥2.3b |
603102 Weihai Baihe Biology Technological | 2.8x | n/a | CN¥2.4b |
600530 Shanghai Jiaoda OnllyLtd | 9.4x | n/a | CN¥2.7b |
600249 Liuzhou Liangmianzhen | 2.5x | n/a | CN¥2.8b |
688793 Shenzhen Breo Technology | 2.2x | 19.9% | CN¥2.5b |
Price-To-Sales vs Peers: 688793 is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (4.1x).
Price to Sales Ratio vs Industry
How does 688793's PS Ratio compare vs other companies in the CN Personal Products Industry?
| 0 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 688793 is good value based on its Price-To-Sales Ratio (2.2x) compared to the CN Personal Products industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is 688793's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.2x |
| Fair PS Ratio | 2.6x |
Price-To-Sales vs Fair Ratio: 688793 is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥30.35 | CN¥35.70 +17.6% | 9.8% | CN¥39.20 | CN¥32.20 | n/a | 2 |
| Nov ’25 | CN¥29.31 | CN¥35.70 +21.8% | 9.8% | CN¥39.20 | CN¥32.20 | n/a | 2 |
| Oct ’25 | CN¥39.57 | CN¥35.70 -9.8% | 9.8% | CN¥39.20 | CN¥32.20 | n/a | 2 |
| Sep ’25 | CN¥33.38 | CN¥35.70 +7.0% | 9.8% | CN¥39.20 | CN¥32.20 | n/a | 2 |
| Aug ’25 | CN¥33.00 | CN¥37.52 +13.7% | 4.5% | CN¥39.20 | CN¥35.84 | n/a | 2 |
| Jul ’25 | CN¥29.00 | CN¥37.52 +29.4% | 4.5% | CN¥39.20 | CN¥35.84 | n/a | 2 |
| Jun ’25 | CN¥31.84 | CN¥37.52 +17.8% | 4.5% | CN¥39.20 | CN¥35.84 | n/a | 2 |
| May ’25 | CN¥32.97 | CN¥37.52 +13.8% | 4.5% | CN¥39.20 | CN¥35.84 | n/a | 2 |
| Apr ’25 | CN¥30.85 | CN¥35.60 +15.4% | 10.1% | CN¥39.20 | CN¥32.00 | n/a | 2 |
| Mar ’25 | CN¥27.60 | CN¥35.60 +29.0% | 10.1% | CN¥39.20 | CN¥32.00 | n/a | 2 |
| Feb ’25 | CN¥28.51 | CN¥40.75 +42.9% | 3.8% | CN¥42.30 | CN¥39.20 | n/a | 2 |
| Jan ’25 | CN¥33.65 | CN¥42.88 +27.4% | 7.6% | CN¥47.13 | CN¥39.20 | n/a | 3 |
| Dec ’24 | CN¥37.38 | CN¥42.88 +14.7% | 7.6% | CN¥47.13 | CN¥39.20 | n/a | 3 |
| Nov ’24 | CN¥36.95 | CN¥42.88 +16.0% | 7.6% | CN¥47.13 | CN¥39.20 | CN¥29.31 | 3 |
| Oct ’24 | CN¥36.56 | CN¥38.95 +6.5% | 0.6% | CN¥39.20 | CN¥38.70 | CN¥39.57 | 2 |
| Sep ’24 | CN¥33.18 | CN¥40.35 +21.6% | 4.9% | CN¥43.15 | CN¥38.70 | CN¥33.38 | 3 |
| Aug ’24 | CN¥40.30 | CN¥39.46 -2.1% | 9.5% | CN¥43.15 | CN¥34.29 | CN¥33.00 | 3 |
| Jul ’24 | CN¥38.50 | CN¥39.46 +2.5% | 9.5% | CN¥43.15 | CN¥34.29 | CN¥29.00 | 3 |
| Jun ’24 | CN¥36.59 | CN¥39.46 +7.9% | 9.5% | CN¥43.15 | CN¥34.29 | CN¥31.84 | 3 |
| May ’24 | CN¥33.96 | CN¥39.46 +16.2% | 9.5% | CN¥43.15 | CN¥34.29 | CN¥32.97 | 3 |
| Apr ’24 | CN¥36.79 | CN¥42.04 +14.3% | 2.6% | CN¥43.15 | CN¥40.94 | CN¥30.85 | 2 |
| Mar ’24 | CN¥39.21 | CN¥39.89 +1.7% | 8.0% | CN¥43.15 | CN¥35.57 | CN¥27.60 | 3 |
| Feb ’24 | CN¥36.68 | CN¥38.26 +4.3% | 7.0% | CN¥40.94 | CN¥35.57 | CN¥28.51 | 2 |
| Jan ’24 | CN¥35.02 | CN¥32.89 -6.1% | 8.1% | CN¥35.57 | CN¥30.21 | CN¥33.65 | 2 |
| Dec ’23 | CN¥32.98 | CN¥32.89 -0.3% | 8.1% | CN¥35.57 | CN¥30.21 | CN¥37.38 | 2 |
| Nov ’23 | CN¥29.81 | CN¥32.89 +10.3% | 8.1% | CN¥35.57 | CN¥30.21 | CN¥36.95 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
SYoung Group
CN¥5.0b
Engages in the research and development, production, and sale of cosmetic products in China.
300740
CN¥12.86
7D
-2.2%
1Y
-22.7%
Sirio Pharma
CN¥6.4b
Operates as a contract manufacturer for dietary supplement industry worldwide.
300791
CN¥27.39
7D
-2.6%
1Y
7.2%
Byhealth
CN¥21.9b
Develops and sells dietary supplements.
300146
CN¥12.97
7D
-4.1%
1Y
-28.8%